CEVA SANTÉ ANIMALE: Company Profile

Background

Overview

Ceva Santé Animale, established in 1999, is a multinational animal health company headquartered in Libourne, France. The company specializes in the research, development, production, and marketing of pharmaceutical products and vaccines for various animal species, including companion animals, poultry, ruminants, and swine. Ceva is recognized as the fifth-largest animal health company globally and the leading French multinational in the sector.

Mission and Vision

Ceva's mission is to provide innovative health solutions for all animals, ensuring the highest level of care and well-being. The company's vision, "Together, beyond animal health," reflects its commitment to advancing animal health and welfare worldwide.

Industry Significance

With a turnover of €1.77 billion in 2024, Ceva has established itself as a significant player in the global animal health industry. The company operates in over 110 countries, employing more than 7,000 people worldwide.

Key Strategic Focus

Core Objectives

Ceva aims to be the first independent player within the top five global animal health companies by 2020. This ambition is supported by a strategic focus on innovation, expansion, and a commitment to the One Health approach, recognizing the interconnectedness of human, animal, and environmental health.

Areas of Specialization

The company specializes in several key areas:

Companion Animals: Providing vaccines and behavioral products for pets.

Poultry: Offering hatchery vaccines, vaccination services, and equipment.

Ruminants: Supplying products for reproduction management, including antibiotic therapies and vaccines.

Swine: Developing a range of products, including antibiotic therapies, reproduction management solutions, and vaccines.

Key Technologies Utilized

Ceva employs advanced technologies in vaccine development, diagnostics, and animal health management. The company invests heavily in preventive veterinary solutions, with vaccines and other health innovations accounting for over half of its product portfolio.

Primary Markets Targeted

Ceva's primary markets include Europe, North America, Latin America, Africa, the Middle East, and Asia-Pacific. The company has a significant presence in emerging markets, such as China, where it acquired a controlling stake in Sichuan Hengtong's animal health subsidiary in 2013.

Financials and Funding

Funding History

Ceva has undergone several management-led buyouts (LBOs) since its inception, with the most recent in 2020, which led to a recomposition of the capital structure and the arrival of new shareholders.

Total Funds Raised

Specific details regarding the total funds raised by Ceva are not publicly disclosed.

Recent Funding Rounds

In 2020, Ceva welcomed a consortium of new investors led by Téthys Invest SAS and Public Sector Pension Investment Board (PSP Investments), alongside existing shareholders, including Ceva’s management and employees (majority shareholders) and Creadev.

Notable Investors

Notable investors include Téthys Invest SAS, PSP Investments, and Creadev.

Intended Utilization of Capital

The capital raised is intended to support Ceva's long-term development strategy, including investments in innovation, expansion into new markets, and the enhancement of its product portfolio.

Pipeline Development

Key Pipeline Candidates

Ceva's pipeline includes vaccines and pharmaceutical products targeting various diseases in companion animals, poultry, ruminants, and swine. The company focuses on developing solutions for emerging infectious diseases and improving animal welfare.

Stages of Clinical Trials or Product Development

Specific details regarding the stages of clinical trials or product development for individual pipeline candidates are not publicly disclosed.

Target Conditions

Ceva targets a range of conditions, including infectious diseases, reproductive issues, and behavioral problems in animals.

Relevant Timelines for Anticipated Milestones

Timelines for anticipated milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Ceva has developed proprietary technologies in vaccine production, diagnostics, and animal health management. The company invests heavily in preventive veterinary solutions, with vaccines and other health innovations accounting for over half of its product portfolio.

Significant Scientific Methods

Ceva employs advanced scientific methods in vaccine development, diagnostics, and animal health management. The company invests heavily in preventive veterinary solutions, with vaccines and other health innovations accounting for over half of its product portfolio.

AI-Driven Capabilities

Specific details regarding AI-driven capabilities are not publicly disclosed.

Leadership Team

Key Executive Profiles

Dr. Marc Prikazsky: Chairman and CEO since January 2007.

Dr. Thierry Le Flohic: Chief Operating Officer.

Pascal Anjot: Chief Financial Officer.

Dr. Gabriel Rshaid: Head of Pharmaceutical Development, Innovation, Strategy, Business Development & Market Access.

Loic Pelourdeau: Head of Human Resources.

Leadership Changes

In 2020, Ceva underwent a recomposition of its capital structure, welcoming new investors and reinforcing its long-term development strategy.

Competitor Profile

Market Insights and Dynamics

The global animal health market is characterized by steady growth, driven by increasing demand for animal protein, rising awareness of animal health, and the need for sustainable farming practices. Ceva competes with other major players in the industry, including Zoetis, Merck Animal Health, and Elanco.

Competitor Analysis

Zoetis: A leading global animal health company offering a broad range of medicines and vaccines.

Merck Animal Health: Provides a comprehensive portfolio of veterinary pharmaceuticals, vaccines, and health management solutions.

Elanco: Specializes in animal health products, including vaccines, parasiticides, and antibiotics.

Strategic Collaborations and Partnerships

Ceva has established several strategic collaborations and partnerships to enhance its market position and innovation capacity:

Wageningen Bioveterinary Research (WBVR): In 2018, Ceva and WBVR announced a collaboration to develop veterinary vaccines for the control of emerging infectious animal diseases, such as Rift Valley fever and influenza.

International Cat Care (ICC): Ceva has been awarded six International Cat Care (ICC) Easy to Give Awards and three ICC Cat Friendly Awards for products in the Feliway range, recognizing its commitment to feline well-being.

Operational Insights

Ceva's strategic considerations include maintaining a strong focus on innovation, expanding its global presence, and adhering to its One Health approach to address the interconnectedness of human, animal, and environmental health. The company differentiates itself through its commitment to preventive medicine and animal welfare.

Strategic Opportunities and Future Directions

Ceva's strategic roadmap includes: